|Other Names||Calcipressin-3, Down syndrome candidate region 1-like protein 2, Myocyte-enriched calcineurin-interacting protein 3, MCIP3, Regulator of calcineurin 3, RCAN3, DSCR1L2|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6317a was selected from the C-term region of human DSCR1L2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Inhibits calcineurin-dependent transcriptional responses by binding to the catalytic domain of calcineurin A. Could play a role during central nervous system development (By similarity).|
|Tissue Location||Highest expression in heart, skeletal muscle kidney, liver and peripheral blood leukocytes. Lower expression in all other tissues|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
DSCR1L2 inhibits calcineurin-dependent transcriptional responses by binding to the catalytic domain of calcineurin A, and may play a role during central nervous system development. Highest expression occurs in heart, skeletal muscle kidney, liver and peripheral blood leukocytes.
Strippoli, P., et al., Genomics 64(3):252-263 (2000).
If you have any additional inquiries please email technical services at email@example.com.